CoChat

Differential Effect of Helicobacter pylori Eradication on Time‐Trends in Brady/Hypokinesia and Rigidity in Idiopathic Parkinsonism: Report on Completion of a Randomized, Double‐Blind, Placebo‐Controlled Efficacy Study

Open access
Dobbs, Sylvia M., Dobbs, R. John, Weller, Clive, Charlett, André, Bjarnason, Ingvar T., Lawson, Andrew J., Letley, Darren, Harbin, Lucy, Price, Ashley B., Ibrahim, Mohammad A. A., Oxlade, Norman L., Bowthorpe, James, Leckstroem, Daniel, Smee, Cori, Plant, J. Malcolm, Peterson, Dale W. · 2010 · Helicobacter
Cited by 75

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Background: We examine the effect of eradicating Helicobacter in idiopathic parkinsonism (IP). Marked deterioration, where eradication‐therapy failed, prompted an interim report in the first 20 probands to reach de‐blinding. The null‐hypothesis, “eradication has no effect on principal outcome, mean stride length at free‐walking speed,” was rejected. We report on study completion in all 30 who had commenced post‐treatment assessments. Methods: This is a randomized, placebo‐controlled, parallel‐group efficacy study of eradicating biopsy‐proven (culture and/or organism on histopathology) Helicobacter pylori infection on the time course of facets of IP, in probands taking no, or stable long‐t ½, anti‐parkinsonian medication. Persistent infection at de‐blinding (scheduled 1‐year post‐treatment) led to open active eradication‐treatment. Results: Stride length improved (73 (95% CI 14–131) mm/year, p = .01) in favor of “successful” blinded active over placebo, irrespective of anti‐parkinsonian medication, and despite worsening upper limb flexor rigidity (237 (57–416) Nm × 10−3/year, p = .01). This differential effect was echoed following open active, post‐placebo. Gait did not deteriorate in year 2 and 3 post‐eradication. Anti‐nuclear antibody was present in all four proven (two by molecular microbiology only) eradication failures. In the remainder, it marked poorer response during the year after eradication therapy, possibly indicating residual “low‐density” infection. We illustrate the importance of eradicating low‐density infection, detected only by molecular microbiology, in a proband not receiving anti‐parkinsonian medication. Stride length improved (424 (379–468) mm for 15 months post‐eradication, p = .001), correction of deficit continuing to 3.4 years. Flexor rigidity increased before hydrogen‐breath‐test positivity for small intestinal bacterial overgrowth (208 (28–388) Nm × 10−3, p = .02), increased further during (171 (67–274), p = .001) (15–31 months), and decreased (136 (6–267), p = .04) after restoration of negativity (32–41 months). Conclusion: Helicobacter is an arbiter of progression, independent of infection‐load.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1523-5378.2010.00768.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 75

Metadata

Authors
Dobbs, S. M., Dobbs, R. J., Weller, C., Charlett, A., Bjarnason, I. T., Lawson, A. J., Letley, D., Harbin, L., Price, A. B., Ibrahim, M. A. A., Oxlade, N. L., Bowthorpe, J., Leckstroem, D., Smee, C., Plant, J. M., & Peterson, D. W.
Venue
Helicobacter
Publisher
Wiley
Published
2010-07-16
Volume
15
Issue
4
Pages
279-294
ISSN
  • 1083-4389 (ISSN-L)
  • 1523-5378
OpenAlex
W1554600569
Cited by
75
References
7
FWCI
2.60
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Differential Effect of Helicobacter pylori Eradication on Time‐Trends in Brady/Hypokinesia and Rigidity in Idiopathic Parkinsonism: Report on Completion of a Randomized, Double‐Blind, Placebo‐Controlled Efficacy Study. https://app.cochat.ai/papers/10.1111/j.1523-5378.2010.00768.x
The paper
Dobbs, S. M., Dobbs, R. J., Weller, C., Charlett, A., Bjarnason, I. T., Lawson, A. J., Letley, D., Harbin, L., Price, A. B., Ibrahim, M. A. A., Oxlade, N. L., Bowthorpe, J., Leckstroem, D., Smee, C., Plant, J. M., & Peterson, D. W. (2010). Differential Effect of Helicobacter pylori Eradication on Time‐Trends in Brady/Hypokinesia and Rigidity in Idiopathic Parkinsonism: Report on Completion of a Randomized, Double‐Blind, Placebo‐Controlled Efficacy Study. Helicobacter. https://doi.org/10.1111/j.1523-5378.2010.00768.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.